Treatment Study

Fludarabine (a nucleoside analogue)

Data based on 644 patient profiles

62 patients indicated they took Fludarabine treatment as their first series or second series if their first series was Watchful Waiting (8). For this entire group the average response time was 1.68 years and the median response time was 1.48 years. The average age of this group was 59.7 years and the median age was 60.9 years. There dose not seem to be any correlation between age and response time. The age span was from 35 to 81.

17 out of the 62 have indicated they have taken a second series of treatment. The average response time for this group was 1.41 years and the median response time was 1.00 years.

45 patients indicated no other treatment at the time they sent in their profile. The average response time for this group was 1.78 years and the median response time was 1.52 years. If and when profiles are updated with more recent information these numbers need to be recalculated.

20 patients indicated they took a combination treatment with Fludarabine. The average response time for this group was 1.34 years and the median response time was 0.93 years. Only 5 out of the 20 indicated taking a second series of treatment.

Please note the data supplied by patients were ranges not absolute numbers. For this study the average of the range given were used in calculating the following information. These numbers should only be used to show trends.

The average reduction in IgM 6 months after completing the first series of Fludarabine was 2481 and the median was 2250 (Out of the 62 patient profiles only 23 had enough data to calculate a 6 month reduction in IgM).

The average reduction in WBC 6 months after completing the first series of Fludarabine was 1.4 and median was 1.5

The average Increase in RBC 6 months after completing the first series of Fludarabine was 0.2 and median was 0.0

The average increase in HGB 6 months after completing the first series of Fludarabine was 2.1 and median was 1.9

Definitions of terms:

Average: Add all the values in a set numbers and then divide that sum by total of numbers in the set.

Median: The value in the center of a set of values.

Response time: Is from the start of a series of treatment to the start of the next series of treatment.

Series: A set number of courses of a drug.  This is followed by an undetermined time period not requiring treatment. For example: 3 Courses of 2CdA over a 6 month period (this is one series) or some quantity of Cytoxan daily/weekly over two years (this is also one series).  

Blood Test Data Summary

	IgM before 1st	IgM after 1st	Series1 6 Month reduction	IgM before 2nd	IgM Most Recent
Average	4736.34	2823.03	2480.77	3864.88	2474.5
Median	4749.5	2249.5	2250	2749.5	2249.5

	WBC before 1st	WBC after 1st	Series1 6 Month reduction	WBC before 2nd	WBC Most Recent
Average	5.2	4.1	1.4	4.6	4.5
Median	5.5	4.2	1.5	4.2	4.2

	RBC before 1st	RBC after 1st	Series1 6 Month reduction	RBC before 2nd	RBC Most Recent
Average	3.6	3.8	-0.2	3.4	4.0
Median	3.2	3.7	0.0	3.2	3.7

	HBC before 1st	HGB after 1st	Series1 6 Month reduction	HGB Before 2nd	HGB Most Recent
Average	10.1	12.1	-2.1	10.7	12.3
Median	9.7	12.7	-1.9	11.2	12.7

Treatment Side Effects

The following are the most common side effects indicated by patients taking this treatment.

Not all side effects are include (only the most common for this treatment was included).

Treatment Text	SideEffects Code	SideEffect Text
Fludarabine (a nucleoside analogue)	1	Fatigue	22%
	3	Anemia	13%
	4	Lethargy	8%
	6	Loss of Appetite	8%
	21	Shingles or other Rash	5%
	99	No Side Effects	14%

The following data is a small part of the total detail data used to generate all the summary information for this report. The total quantity of material is available upon request.

Patient Data

_______________ indicates patient was on Watchful Waiting before taking their first series of Fludarabine.

_______________ indicates patient took a second series of treatment

_______________ indicates patient took a combination treatment with Fludarabine

Id	Private	Age series1	Series	Treatment	Date from	Date to	Response Time	Response time	Response time (ongoing)	email
15	No	64.77	2	Fludarabine (a nucleoside analogue)	1/1/1997	2/1/1999	2.08	2.08		gelberj@newschool.edu
20	No	55.20	1	Fludarabine (a nucleoside analogue)	10/16/1995	1/8/1996	3.02	3.02		flb134@email.msn.com
59	Yes	41.15	1	Fludarabine (a nucleoside analogue)	1/1/1994	7/1/1994	3.00	3.00
72	No	77.73	1	Fludarabine (a nucleoside analogue)	12/1/1998	5/1/1999		1.17	1.17	adelaidewada9@aol.com

Patients with Fludarabine Combination Treatment

Id	Private	Age series1	Series	Treatment	Date from	Date to	Response Time	Response time	Response time (ongoing)	email
98	No	50.61	2	Fludarabine (a nucleoside analogue) Rituxin Cytoxan	3/1/1999	3/1/2000		0.93	0.93	pwisner@sirius.com

Blood Test Data Treatment Fludarabine

_______________ indicates patient was on Watchful Waiting before taking their first series of Fludarabine

ID	IgM before 1st	IgM after 1st	Series1 .6 Month reduction	IgM before 2nd	IgM Most Recent	WBC before 1st	WBC after 1st	Series1 6 Month reduction	WBC before 2nd	WBC Most Recent	RBC before 1st	RBC after 1st	Series1 6 Month reduction	RBC before 2nd	RBC Most Recent	HBC before 1st	HGB after 1st	Series1 6 Month reduction	HGB Before 2nd	HGB Most Recent
20	11749.5	6249.5	5500	6249.5	3249.5	6.2	4.7	1.5	6.2	7.2	3.2	3.7	-0.5	4.7	4.2	10.45	13.2	-2.75	13.2	13.7
59	1249.5	1749.5	-500	1249.5		6.7	4.7	2	6.7	4.2				2.5		9.2	11.7	-2.5	5	12.2
72	3249.5				4249.5	3.2				3.2	2.7				2.7	10.45				9.2
101						2.2	2.7	-0.5			2.7	2.7	0			9.7	9.7	0
134	5249.5					2.7
15	2749.5	1249.5	1500	2749.5	2749.5	3.7	4.2	-0.5	4.2	4.2	4.7	4.2	0.5	4.2	4.2	12.2	12.2	0	12.7	12.7